Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Sue Ann Costa Clemens, Lily Weckx, Ralf Clemens, Ana Verena Almeida Mendes, Alessandra Ramos Souza, Mariana V Silveira, Suzette Nascimento Farias da Guarda, Maristela Miyamoto de Nobrega, Maria Isabel de Moraes Pinto, Isabela G S Gonzalez, Natalia Salvador, Marília Miranda Franco, Renata Navis de Avila Mendonça, Isabelle Silva Queiroz Oliveira, Bruno Solano de Freitas Souza, Mayara Fraga, Parvinder Aley, Sagida Bibi, Liberty Cantrell, Wanwsia Dejiratissai, Xinxue Liu, Juthapip Mongkolpaphaya, Piyada Supasa, Gavin R Scrutton, Teresa Lambe*, Merryn Voysey*, Andrew J Pollard*, and the RHH-001 study team

Summary

Introduction The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has been widely used in a two-dose schedule. We assessed whether a third dose of the homologous or a different vaccine could boost immune responses.

Methods RHH-001 is a phase 4, participant masked, two centre, safety and immunogenicity study of Brazilian adults (18 years and older) in São Paulo or Salvador who had received two doses of CoronaVac 6 months previously. Thirty-four participants were randomly assigned (equally) to three groups: homologous, heterologous, or placebo. All vaccinated groups had substantial IgG antibody concentrations: the geometric fold-rise was 77 (95% CI 67–88) for Ad26.COV2-S, 152 (134–173) for BNT162b2, 90 (77–104) for ChAdOx1 nCoV-19, and 12 (11–14) for CoronaVac. All heterologous regimens induced anti-spike IgG responses at day 28 that were superior to homologous booster responses: geometric mean ratios (heterologous vs homologous) were 6.7 (95% CI 5.8–7.7) for Ad26.COV2-S, 13.4 (11.6–15.3) for BNT162b2, and 7.0 (6.1–8.1) for ChAdOx1 nCoV-19. There were three serious adverse events. Three of which were considered possibly related to the vaccine received: one in the BNT162b2 group and two in the Ad26.COV2-S group. All participants recovered and were discharged home.

Interpretation Antibody concentrations were low at 6 months after previous immunisation with two doses of CoronaVac. However, all four vaccines administered as a third dose induced a significant increase in binding and neutralising antibodies, which could improve protection against infection. Heterologous boosting resulted in more robust immune responses than homologous boosting and might enhance protection.

Funding Ministry of Health, Brazil.
Introduction

The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac; Sinovac Life Sciences, China and Instituto Butantan, Brazil) has been widely used in large-scale vaccination programmes in many countries.

In phase 3 randomised trials, two doses of CoronaVac showed varying levels of short-term efficacy against symptomatic COVID-19 (<6 months since vaccination), with efficacy and effectiveness estimates of 83·5% in Turkey,1 50·7% in Brazil,2 and 65·9% in Chile.3

Efficacy against COVID-19 hospitalisation was higher with 83·7% (95% CI 58·0–93·7) efficacy in Brazil2 and 65·9% in Chile.3 As a result of waning immunity after two doses of COVID-19 vaccines and some evidence of reduced effectiveness, many countries are now considering offering third or booster doses. We searched PubMed for studies in English from Jan 1 to Dec 31, 2021 on booster doses of vaccines for individuals who had received two priming doses of the inactivated vaccine, CoronaVac. We found that heterologous boosting of CoronaVac with recombinant adenovirus type-5 COVID-19 vaccine produced greater neutralising antibody titres than did homologous boosting in a randomised trial in China. Similar findings are included in a preprint from Thailand comparing heterologous boosting with ChAdOx1 nCoV-19 after CoronaVac.4 In mouse models, heterologous boosting of CoronaVac with one of three different vaccines resulted in better outcomes than did homologous boosting.5,6

In this study, we compared the safety and immunogenicity of a third heterologous booster dose of one of three different vaccines, with a homologous boost in adults in Brazil who previously received two doses of CoronaVac.

Methods

Study design and participants

In RHH-001, we conducted a phase 4, randomised, participant blind, safety and immunogenicity study of a third heterologous booster dose of either the recombinant adenoviral vectored ChAdOx1 nCoV-19 vaccine (AZD1222, AstraZeneca, in combination with Fiocruz), mRNA vaccine (BNT162b2, Pfizer/BioNTech), or recombinant adenoviral vectored vaccine (Ad26.COV2-S, Janssen), compared with a third homologous boost with inactivated whole virion COVID-19 vaccine CoronaVac. The two study sites were in Brazil (Hospital São Rafael, Salvador, and CRIE UNIFESP, São Paulo).

Participants were eligible if they were 18 years or older; had received their second doses of CoronaVac 182 days (plus or minus 30 days) before enrolment; female participants were not pregnant, puerperal, or nursing; and all participants had given written informed consent. Participant exclusion criteria were history of allergies; and all participants had given written informed consent. Participant exclusion criteria were history of allergies; and all participants had given written informed consent. Participant exclusion criteria were history of allergies; and all participants had given written informed consent.
(excluding people with Hashimoto’s thyroiditis, vitiligo, psoriasis, lupus discords, HIV positive, or on HIV treatment); people on immunosuppressive medications within 15 days of vaccine; receipt of other investigational products, other vaccines within 14 days of enrolment or plans to receive vaccine within 28 days of vaccination, monoclonals within 9 months of day 1 or planned during the study, intravenous immunoglobulin, or other blood products; and any condition that could interfere with the primary objectives or represent additional risk to participants. Ethical approval was given by the National Ethical Review Committee, Comissão Nacional de Ética em Pesquisa.

**Randomisation and masking**
Participants were randomly assigned to receive one of four different booster vaccines of either heterologous dosing with ChAdOx1 nCoV-19, BNT162b2, or Ad26.COVID2-S, or homologous dosing with CoronaVac in a 5:6:5:5 ratio. The computer randomisation was conducted using RedCAP, stratified by site, age group (18–60 years or 61 years and older), and day of randomisation, with a block size of 42. Participants were enrolled from both age groups in equal numbers. The randomisation ratio was chosen to minimise vaccine wastage as the vaccines were supplied in five, six, or ten dose vials; therefore, 42 participants could be enrolled and vaccinated in a block with no wastage (appendix p I). Participants were masked to the vaccine that they had received until the second visit, 28 days after vaccination. Blood samples for immunogenicity were taken before vaccination and at day 28 after vaccination. Study staff were aware of vaccine allocations, but laboratory staff remained masked.

---

**Figure 1:** Trial profile

mITT=modified intention to treat population. *It is possible to have more than one reason for exclusion per person; therefore, the number of people excluded is less than the sum of the reasons for exclusion. †The one person incorrectly given CoronaVac was included in the mITT.
**Procedures**

CoronaVac is an inactivated COVID-19 vaccine; a 0·5 mL dose contains 600 SU of inactivated SARS-CoV-2 virus. ChAdOx1 nCoV-19 is a recombinant chimpanzee adenovirus that encodes full length spike SARS-CoV-2 glycoprotein; a 0·5 mL dose contains 5×10¹⁰ viral particles. BNT162b2 is an mRNA vaccine incorporated into lipid nanoparticles; a 0·3 mL dose contains 30 µg of SARS-CoV-2 spike protein messenger RNA. Ad26.COV2-S is a recombinant adenovirus type 26 that encodes SARS-CoV-2 spike glycoprotein used as a dose of 0·5 mL containing 5×10¹⁰ viral particles. All vaccines were administered intramuscularly.

A validated multiplexed immunoassay (3-plex ECL based assay on the MSD platform, PPD Vaccines, Richmond, VA, USA) was used to measure anti-spike, receptor binding domain, and nucleocapsid responses. The upper limit of the assay was 2 million arbitrary units per millilitre (AU/mL) and the lower limit was 1 AU/mL.

Antibody neutralisation titres on a random subset of 200 participants were measured with a lentivirus-based pseudovirus particle expressing the D614 SARS-CoV-2 spike protein (Monogram Biosciences, South San Francisco, CA, USA). Results are presented as inhibitory concentration of serum achieving 50% neutralisation of virus (IC₅₀). The lower limit of the assay was 40 IC₅₀.

A random subset of 80 participants (20 per group, stratified by age) were tested for live virus neutralisation using delta (B.1.6172) and omicron (B.1.1.529) variants of SARS-CoV-2 virus with results reported as a value of 50% focus reduction neutralisation test (FRNT₅₀), which is the reciprocal dilution of serum that neutralises 50% of the input virus. The lower limit was 20 FRNT₅₀. For all assays, values above the upper limit were analysed at the upper limit, and values below the lower limit were substituted with half the lower limit. Samples were collected and stored locally before shipping to the centralised laboratories for testing.

**Outcomes**

The primary outcome was non-inferiority of anti-spike IgG antibodies 28 days after the booster dose in the heterologous boost groups compared with homologous regimen. Secondary outcomes included neutralising antibody titres at day 28, local and systemic reactogenicity profiles self-reported by diary cards, adverse events, and serious adverse events (appendix pp 12–79).

**Statistical analysis**

Antibody data were log-transformed before the analysis. The study used a non-inferiority design with the main hypothesis being that the anti-spike IgG induced by heterologous vaccine schedules is non-inferior to antibodies induced by the homologous vaccine schedule, using a non-inferiority margin for the geometric mean ratios (GMRs; heterologous vs homologous) of 0·67. GMRs were calculated by taking the anti-log of the mean ratios, adjusting for baseline antibody concentrations and age group was also tested but was not significant and was not included in the final model.

The primary analysis population included people who were randomly assigned, received at least one dose of the study vaccines or comparator, and provided post-vaccination immunogenicity data (ie, the modified intention-to-treat population). Missing data were not imputed. Confidence

---

**Table 1**: Baseline characteristics of primary analysis population

|                | Overall (n=1205) | Ad26.COV2-S (n=295) | BNT162b2 (n=333) | ChAdOx1 nCoV-19 (n=296) | CoronaVac (n=281) |
|----------------|------------------|---------------------|------------------|-------------------------|------------------|
| **Sex**       |                  |                     |                  |                         |                  |
| Male          | 476 (39·5%)      | 114 (38·6%)         | 129 (38·7%)      | 117 (39·5%)             | 116 (41·3%)      |
| Female        | 729 (60·5%)      | 181 (61·4%)         | 204 (61·3%)      | 179 (60·5%)             | 165 (58·7%)      |
| **Age**       |                  |                     |                  |                         |                  |
| 18-60 years   | 616 (51·1%)      | 153 (51·9%)         | 165 (49·5%)      | 150 (50·7%)             | 148 (52·7%)      |
| Over 61 years | 589 (48·9%)      | 203 (68·8%)         | 230 (69·1%)      | 200 (67·6%)             | 181 (64·4%)      |
| **Race**      |                  |                     |                  |                         |                  |
| White         | 814 (67·6%)      | 203 (68·8%)         | 230 (69·1%)      | 200 (67·6%)             | 181 (64·4%)      |
| Black         | 57 (4·7%)        | 14 (4·7%)           | 17 (5·1%)        | 13 (4·4%)               | 13 (4·6%)        |
| Mixed         | 275 (22·8%)      | 65 (22·0%)          | 68 (20·4%)       | 70 (23·6%)              | 72 (25·6%)       |
| Asian         | 57 (4·7%)        | 14 (4·7%)           | 17 (5·1%)        | 12 (4·1%)               | 15 (5·3%)        |
| Not given     | 2 (0·2%)         | 0 (0%)              | 1 (0·3%)         | 1 (0·3%)                | 0 (0%)           |
| **Medical history** |          |                     |                  |                         |                  |
| Type 2 diabetes | 127 (10·5%)    | 34 (11·5%)          | 21 (6·3%)        | 39 (13·2%)              | 33 (11·7%)       |
| Heart failure | 9 (0·7%)         | 3 (1·0%)            | 1 (0·3%)         | 2 (0·7%)                | 3 (1·1%)         |
| COPD          | 9 (0·7%)         | 1 (0·3%)            | 2 (0·6%)         | 2 (0·7%)                | 4 (1·4%)         |
| Hypertension | 365 (30·3%)      | 84 (28·5%)          | 91 (27·3%)       | 99 (33·4%)              | 91 (32·4%)       |
| Cancer        | 126 (10·5%)      | 27 (9·2%)           | 33 (9·9%)        | 38 (12·8%)              | 28 (10·0%)       |
| Immunosuppressed | 3 (0·2%)      | 1 (0·3%)            | 2 (0·6%)         | 0 (0%)                  | 0 (0%)           |
| Chronic kidney disease | 7 (0·6%) | 0 (0%)              | 1 (0·3%)         | 3 (1%)                  | 3 (1·1%)         |
| Coronary artery disease | 61 (5·1%) | 7 (2·4%)            | 18 (5·4%)        | 17 (5·7%)               | 19 (6·8%)        |
| Cardiomyopathy | 7 (0·6%)        | 2 (0·7%)            | 3 (0·9%)         | 1 (0·3%)                | 1 (0·4%)         |
| Sickle cell anemia | 1 (0·1%)      | 0 (0%)              | 1 (0·3%)         | 0 (0%)                  | 0 (0%)           |
| Obesity       | 80 (6·6%)        | 24 (8·1%)           | 21 (6·3%)        | 20 (6·8%)               | 15 (5·3%)        |
| HIV           | 2 (0·2%)         | 0 (0%)              | 2 (0·6%)         | 0 (0%)                  | 0 (0%)           |
| **Time since second vaccine, days** |          |                     |                  |                         |                  |
| Mean (SD)     | 178·4 (9·9)      | 178·7 (9·6)         | 178·6 (10·1)     | 178·9 (9·7)             | 177·4 (10·3)     |

COPD=Copnic obstructive pulmonary disease.
intervals for percentages were computed using the Binomial Exact (Clopper-Pearson) method. All analyses were done using R, version 4.1.1

Assuming a standard deviation of 0.4 for anti-spike IgG 28 days after the booster dose, 90% power, and alpha of 0.0167 due to three comparisons of heterologous versus homologous schedules, the study required 124 evaluable people per age group and per study group. Allowing for 20% loss to follow-up or incomplete data and the required randomisation ratio, 1240 people were planned for enrolment.

This study was registered with Registro Brasileiro de Ensaios Clínicos, number RBR – 9nn3scw.

Role of the funding source
The study was funded by the Ministry of Health, Brazil and sponsored by Instituto D’Or de Pesquisa e Ensino. The Oxford investigators were supported by the NIHR Oxford Biomedical Research Centre. The funders had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit the paper for publication.

Results
Between Aug 16, and Sep 1, 2021, 1240 participants were randomly assigned in two age groups (18–60 years and 61 years or older), of whom 1239 were vaccinated. One participant was vaccinated with a vaccine to which they had not been randomly assigned (figure 1). 1205 (97%) returned for their day 28 visit and were eligible for inclusion in the primary analysis.

Participants included in the primary analysis ranged in age from 21 years to 98 years (median 60 years). The median time since receipt of the second dose of CoronaVac was 180 days (range 152–210). Of the 1205 participants, 729 (60.5%) were female and 814 (67.6%) were White. The most common pre-existing comorbidity was hypertension, present in 365 (30.3%) participants. Baseline characteristics were balanced across the four vaccine arms of the trial (table 1).

The most common solicited local vaccine reaction in the first 7 days was injection site pain by 183 (60%) of 305 for Ad26.COV2-S, 256 (76%) of 339 for BNT162b2, 192 (63%) of 304 for ChAdOx1 nCoV-19, and 114 (39%) of 291 for CoronaVac. Headaches were common for Ad26.COV2-S (137 [45%] of 305) and ChAdOx1 nCoV-19 recipients (148 [49%] of 304), compared with BNT162b2 (102 [30%] of 339) and CoronaVac (44 [14%] of 309). Myalgia was also commonly reported in 121 (40%) of 305 for Ad26.COV2-S group, in 77 (23%) of 339 for BNT162b2 group, 130 (43%) of 304 for ChAdOx1 nCoV-19, and in 30 (10%) of 291 recipients of CoronaVac. Fever and chills were common for Ad26.COV2-S (51 [16%] and 39 [12%] of 305) and ChAdOx1 nCoV-19 (44 [15%] and 99 [33%] of 304), but not for recipients of BNT162b2 (seven [2%] and 29 [9%] of 339) or CoronaVac (two [1%] and 21 [7%] of 291; figure 2).

There were five serious adverse events recorded. Three serious adverse events were considered possibly related to the vaccine received: in the BNT162b2 group, a woman of 83 years had a pulmonary embolism and deep vein thrombosis 2 days after vaccination; in the Ad26.COV2-S group, a woman of 52 years had a subconjunctival haemorrhage 2 days after vaccination, and a man of 71 years had a pulmonary embolism 28 days after vaccination. Unrelated serious adverse events included one case of bullous erysipelas (ChAdOx1 nCoV-19), and one case of coronary arterial disease requiring stent insertion (Ad26.COV2-S). All participants recovered and were discharged home. There were no COVID-19 cases identified during the study.

At baseline there were no significant differences in anti-spike IgG across the four randomised groups (p=0.26). At day 28 after the booster vaccine all groups had a substantial rise in antibody concentrations (appendix p 3). The geometric fold-rise from baseline to day 28 was 77 (67–88) for Ad26.COV2-S, 152 (134–173) for BNT162b2, 90 (95% CI 77–104) for ChAdOx1 nCoV-19, and 52 (44–62) for CoronaVac.
nCoV-19, and 12 (11–14) for CoronaVac (figure 3; appendix p 3).

All heterologous regimens were non-inferior to CoronaVac. Superiority comparisons were conducted and all heterologous regimens had anti-spike IgG at day 28 that was superior to that induced by the homologous boost (all p<0.0001, table 2). GMRs were 6·7 (95% CI 5·8–7·7) for Ad26.COV2-S, 13·4 (11·6–15·3) for BNT162b2, and 7·0 (6·1–8·1) for ChAdOx1 nCoV-19 (table 2, figure 3). Similar responses were seen with anti-receptor binding domain IgG (appendix p 7–8) but not with anti-nucleocapsid IgG, which was raised in participants receiving the CoronaVac boost containing the inactivated whole virus (appendix p 5–6). Responses in older adults were 19% lower than in younger adults at day 28, across all vaccines when tested in a linear model adjusted for vaccine group and baseline antibody levels (GMR 0·81 [95% CI 0·73–0·89] in 61 years and older vs 18–60 years, adjusted for vaccine group and baseline anti-spike IgG). In the older age group, the geometric fold-rise was 78·8 (95% CI 65·1–95·2) for Ad26.COV2-S, 165·4 (138·1–198·1) for BNT162b2, 91·5 (72·6–115·2) for ChAdOx1 nCoV-19, and 12·5 (10·3–15·2) for CoronaVac.

Pseudovirus neutralisation titres were available on a random subset of 200 participants. 6 months after the second dose of CoronaVac and before the booster, 28 (14%) of the 194 participants (95% CI 9·8–20·2) had detectable neutralising antibodies on this assay. This value was lower in older adults (nine [9%] of 101, 95% CI 4·2–16·2) than in adults aged 18–60 years (19 [20%] of 93, 12·8–30·1; p=0·022). All participants in the three heterologous booster groups had neutralisation titres that were above the lower limit of detection 28 days after vaccination compared with 38 (83%) of 46 responders (95% CI 68·6–92·2) in the homologous CoronaVac arm. All heterologous regimens were superior to the homologous boost regimen (all p<0·0001), with GMRs of 8·7 (5·9–12·9) for Ad26.COV2-S, 21·5 (14·5–31·9) for BNT162b2, and 10·6 (7·2–15·6) for ChAdOx1 nCoV-19 (figure 4, table 2; appendix p 9–10).

Neutralising antibody titres measured by a live virus assay were above the lower limit of detection in 75 (94%) of 80 participants tested at day 28 for the delta variant and in 61 (76%) of 80 participants for the omicron variant (figure 5). The geometric mean titres for the four booster vaccines differed significantly at day 28 for both omicron and delta (both p<0·0001), but the ratio of omicron to delta did not differ between groups (p=0·11; appendix p 14).

**Discussion**

In this study, we have shown that a third dose booster of the four vaccines tested provides a substantial increase in antibody responses after two doses of CoronaVac, when administered about 6 months after the second dose. Very low neutralising antibody concentrations were detected at 6 months after two doses of the inactivated vaccine, CoronaVac, but both homologous and heterologous COVID-19 booster vaccinations were safe and strongly enhanced the humoral immune responses. The magnitude of the immune boost was greater with the adenoviral vectored vaccines (Ad26.COV2-S and ChAdOx1 nCoV-19) and mRNA vaccine (BNT162b2) than with the homologous regimen, with the highest responses reported after an mRNA boost, similar to recent findings following boosting with these vaccines after two priming doses of either mRNA or viral vector vaccines. In older adults, the difference in neutralising antibody titres was 8–22-fold higher for a heterologous boost than for a homologous boost with CoronaVac. In a preprint by Pan and colleagues, a third dose of CoronaVac given 6 months after the second dose resulted in an approximately 20-fold increase in neutralising antibody titres from a low

---

**Figure 3:** Anti-spike IgG by multiplex immunoassay by study day and age

(A) Day 0, (B) day 28, and (C) day 28 responses by age group and booster vaccine allocation.

Dotted line shows upper limit of the assay. The midlines of the boxes show medians and the outer bounds of the boxes show IQRs. Error bars extend to the last data point within 1·5 × IQR above or below the 75th or 25th percentile. Geometric means shown below each group. See table 2 and appendix (p 3) summary statistics and comparisons. Ad26=Ad.26.COV2-S. AU/mL=arbitrary units per millilitre (conversion factor to convert AU/mL units to BAU/mL units using WHO Reference Standard is 0·00645 [95% CI 0·00594–0·00701]). BNT=BNT162b2. ChAd=ChAdOx1 nCoV-19. CV=CoronaVac.
baseline, higher than the 7-fold increase reported here for pseudoneutralising titres, or the 12-fold increase seen for anti-spike IgG. Differences in study population and laboratory assays might account for this discrepancy in absolute booster response, but substantial booster responses were observed in both studies. We also found that the booster doses of viral vector and mRNA vaccines substantially increased neutralising capacity of serum samples for both delta and omicron variants (at least 90% seropositive after booster), but lower responses were seen after a CoronaVac boost with just 35% becoming seropositive against omicron. Similarly, one preprint shows a 1·4-fold increase in anti-omicron neutralising capacity after an mRNA boost following two doses of CoronaVac, when compared with the activity of sera after two doses of the mRNA vaccine.11

One theoretical advantage of inactivated vaccines is that they contain additional viral proteins, including nucleoprotein, which could potentially broaden protection beyond anti-spike protein responses, and reduce the escape of variants from vaccine immunity. We show a 21-fold increase in anti-N IgG concentrations after the homologous boost but it is not clear whether these antibodies can confer clinical protection. Despite the addition of these anti-N responses, neutralising capacity of these sera is lower than those after a viral vector or mRNA boost, even though the latter responses are limited to anti-spike immunity.

Correlates of protection analysis of trial data from the UK phase 3 ChAdOx1 nCoV-19 vaccine efficacy trial showed that a median anti-spike IgG level of 139·106 AU/mL, and a pseudovirus neutralising antibody titre of 982 IC₅₀ (140 IU/mL using the WHO international standard 20/136) was associated with very high protection against symptomatic infection with variants circulating before February, 2021. After the booster, the CoronaVac group had a geometric mean titre that corresponded to the 80% vaccine efficacy correlate, using the values from Feng and colleagues.13 Using the same assays, geometric mean antibody concentrations for the adenoviral- vectored vaccines in this study were 2·4-fold higher than the 90% vaccine efficacy correlate, and the mRNA vectored vaccines in this study were 2·4-fold higher mean antibody concentrations for the adenoviral-vectored vaccines in this study. We also found that the booster doses of viral vector and mRNA vaccines substantially increased neutralising capacity of serum samples for both delta and omicron variants (at least 90% seropositive after booster), but lower responses were seen after a CoronaVac boost with just 35% becoming seropositive against omicron. Similarly, one preprint shows a 1·4-fold increase in anti-omicron neutralising capacity after an mRNA boost following two doses of CoronaVac, when compared with the activity of sera after two doses of the mRNA vaccine.11

One theoretical advantage of inactivated vaccines is that they contain additional viral proteins, including nucleoprotein, which could potentially broaden protection beyond anti-spike protein responses, and reduce the escape of variants from vaccine immunity. We show a 21-fold increase in anti-N IgG concentrations after the homologous boost but it is not clear whether these antibodies can confer clinical protection. Despite the addition of these anti-N responses, neutralising capacity of these sera is lower than those after a viral vector or mRNA boost, even though the latter responses are limited to anti-spike immunity.

Correlates of protection analysis of trial data from the UK phase 3 ChAdOx1 nCoV-19 vaccine efficacy trial showed that a median anti-spike IgG level of 139·106 AU/mL, and a pseudovirus neutralising antibody titre of 982 IC₅₀ (140 IU/mL using the WHO international standard 20/136) was associated with very high protection against symptomatic infection with variants circulating before February, 2021. After the booster, the CoronaVac group had a geometric mean titre that corresponded to the 80% vaccine efficacy correlate, using the values from Feng and colleagues.13 Using the same assays, geometric mean antibody concentrations for the adenoviral- vectored vaccines in this study were 2·4-fold higher than the 90% vaccine efficacy correlate, and the mRNA vectored vaccines in this study were 2·4-fold higher mean antibody concentrations for the adenoviral-vectored vaccines in this study. We also found that the booster doses of viral vector and mRNA vaccines substantially increased neutralising capacity of serum samples for both delta and omicron variants (at least 90% seropositive after booster), but lower responses were seen after a CoronaVac boost with just 35% becoming seropositive against omicron. Similarly, one preprint shows a 1·4-fold increase in anti-omicron neutralising capacity after an mRNA boost following two doses of CoronaVac, when compared with the activity of sera after two doses of the mRNA vaccine.11

WHO has not recommended widespread use of booster doses of COVID-19 vaccines due to continuing inequity in the distribution of first doses of vaccines to many parts of the world.16 However, in their interim statement on Dec 16, 2021, WHO advises that where countries are considering heterologous schedules, vectored or mRNA vaccines can be considered as third doses in those who received inactivated vaccines for initial doses.16 Our study shows that either of the four vaccines tested will produce a strong immune boost as a third dose after two doses of CoronaVac; however, heterologous boosting produced a substantially better response in this study. This finding might be especially relevant for the older adult population. It is not yet clear how long immunity will persist after a third dose and follow up at 6 months in this study will provide a comparison of antibody waning across the four vaccines tested.

The lowest reactogenicity was reported after CoronaVac, with heterologous boosting in our study reflects similar

---

### Table 2: Comparisons of heterologous versus homologous regimes

| Vaccine | Anti-spike IgG by multiplex immunoassay | Pseudovirus neutralisation titres |
|---------|----------------------------------------|----------------------------------|
|         | All participants | 18–60 years | 61 years and over | All participants | 18–60 years | 61 years and over |
|         | Number of participants | Geometric mean ratio | Number of participants | Geometric mean ratio | Number of participants | Geometric mean ratio |
| Ad26.COV2-S | 294 | 6·7 (5·8–7·7)† | 152 | 6·1 (5·1–7·2) | 142 | 7·3 (5·8–9·2) |
| BNT162b2 | 333 | 13·4 (11·6–15·3)† | 165 | 12·1 (10·3–14·2) | 168 | 15·0 (12·0–18·6) |
| ChAdOx1 nCoV-19 | 296 | 7·0 (6·1–8·1)† | 150 | 6·4 (5·5–7·6) | 146 | 7·6 (6·1–9·5) |
| CoronaVac | 281 | ref <0·0001 | 148 | ref | 133 | ref |

Data are the geometric mean ratio of heterologous versus homologous (95% CI), unless otherwise specified. "p value from ANOVA model comparing log-geometric means across all four groups. *p value <0·0001, values from superiority comparisons comparing heterologous schedules to homologous schedules.
In recent years, there has been widespread interest in the development of vaccines for the prevention of COVID-19. However, the effectiveness and safety of these vaccines vary depending on factors such as age and time since vaccination. To address these concerns, we conducted a study to assess the neutralizing activity of vaccines administered as boosters in people 61 years and older, and to compare the immune responses induced by different vaccines and booster schedules.

**Methods**

We enrolled 100 participants in our study, 50 of whom were assigned to receive either ChAdOx1 nCoV-19 or Ad26.COVID-19 as a booster dose, and the other 50 were assigned to receive BNT162b2 as a booster dose. Participants were stratified into two age groups: 18–60 years and 61 years and older.

**Results**

After the booster vaccination, we measured the neutralizing antibody titres against the original SARS-CoV-2 strain and the delta and omicron variants. The results showed that the neutralizing activity was higher in the younger group compared to the older group, with a greater reactogenicity in some heterologous schedules.

In conclusion, this study shows that use of all four vaccines as a third dose is safe and provides a strong immune response that is more robust than when a heterologous vaccine is used. However, there are some limitations to this study. The study was single-blind for participants until their day 28 visit to ensure recording of vaccine reactions was not influenced by knowledge of the product received, but study staff were aware of vaccine allocations. The main outcomes were laboratory measures of antibody values and laboratory staff remained masked.

**Declaration of interests**

AJP is chair of the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation, but does not participate in policy advice on coronavirus vaccines, and is a member of the WHO.
Strategic Advisory Group of Experts. AJP is an National Institute for Health Research Senior Investigator. TL is named as an inventor on a patent application covering ChAdOx1 nCoV-19. Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. All other authors declare no competing interests.

**Data sharing**

Data are provided as a CSV file in supplementary material.

**Acknowledgments**

The study was funded by the Ministry of Health, Brazil and sponsored by Instituto D’Or de Pesquisa e Ensino. Ethical approval was given by the National Ethical Review Committee, Comissão Nacional de Ética em Pesquisa. The investigators acknowledge, in-kind support from AstraZeneca for the serological assays presented in this manuscript. TL received support from the Chinese Academy of Medical Sciences, Innovation Fund for Medical Science, China (2018-I2M-2-002). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care.

**References**

1. Tantiroyer MD, Dojjanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virus SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet* 2021; 396: 213–22.

2. Palacios R, Batista AP, Albuquerque CSN, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFIVISCOV study. *SSRN* 2021; published online April 14. https://doi.org/10.2139/ssrn.3822780 (preprint).

3. Jara A, Undurraga EA, González C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. *N Eng J Med* 2021; 385: 875–84.

4. Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study. *BMJ* 2021; 374: n387.

5. Li M, Yang J, Wang L, et al. A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *medRxiv* 2021; published online Aug 8. https://doi.org/10.1101/2021.08.03.21226544 (preprint).

6. Pan H, Wu Q, Zeng G, et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomised, placebo-controlled phase 2 clinical trial. *medRxiv* 2021; published online July 25. https://doi.org/10.1101/2021.07.23.21261026 (preprint).

7. Li J, Hou L, Guo X, et al. Heterologous prime-boost immunization with CoronaVac and Covideceza. *medRxiv* 2021; published online Sept 6. https://doi.org/10.1101/2021.09.03.21226362 (preprint).

8. Kanokudom S, Assawakorsri S, Suntronwong N, et al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. *medRxiv* 2021; published online Dec 5. https://doi.org/10.1101/2021.12.01.21267281 (preprint).

9. Spencer AJ, McKay PF, Belij-Rammerstorfer S, et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. *Nat Commun* 2021; 12: 2893.

10. Zhang J, He Q, An C, et al. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. *Emerg Microbes Infect* 2021; 10: 1598–608.

11. Munro AP, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet* 2021; 398: 2258–76.

12. Perez-Then E, Lucas C, Monteiro VS, et al. Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants delta and omicron: the Dominican Republic experience. *medRxiv* 2021; published online Dec 29. https://doi.org/10.1101/2021.12.27.21268459 (preprint).

13. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med* 2021; 27: 2032–40.

14. Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *Lancet* 2021; 398: 856–69.

15. World Health Organisation. Interim statement on booster doses for COVID-19 vaccination. *Update 2021; 4: 2021.* https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination (accessed Jan 10, 2022).

16. WHO. Interim recommendations for heterologous COVID-19 vaccine schedules: interim guidance. Dec 16, 2021. Geneva: World Health Organization, 2021.

17. Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. *Lancet* 2023; 397: 2045–46.